Magazine Article | March 1, 2022

Companies To Watch: Endevica Bio

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Hitting cachexia head-on by inhibiting its core melanocortin mechanism


Endevica Bio is developing a new treatment for cachexia, a severe wasting disease, critical to patients’ survival in cancer and other conditions. Although some previous therapies, such as cytokine inhibitors and mAbs targeting interleukins, have shown activity against cachexia, Endevica has narrowed the focus to the melanocortin system in the brain; in cachexia, the system triggers the release of cytokines that lead to hypermetabolism and its effects driving cachexia. Lead product, coded TCMCB07, attaches to the melanocortin- 4 (M-4) receptor to antagonize the cytokine release and relieve the condition. About to enter the IND-enabling stage for treating cachexia in pancreatic cancer, TCMCB07 is first in the company’s pipeline of peptides, including potential next-generation forms of M-4 inhibitors.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader